| Assessing radiation safety of radiopharmaceutical during radiosynovectomy of knee joint involves sampling peripheral blood, obtaining sample having lymphocytes of first mitosis and performing cytogenetic analysis of chromosomal aberrations | |
| 2024-08-22 | |
| 专利权人 | FEDERAL STATE BUDGETARY INST (FSBI-C) |
| 申请日期 | 2024-08-22 |
| 专利号 | RU2024124502-A; RU2834468-C2 |
| 成果简介 | NOVELTY - Method for assessing radiation safety of radiopharmaceutical during radiosynovectomy of the knee joint involves sampling peripheral blood, obtaining a suspension sample containing lymphocytes of the first mitosis and performing cytogenetic analysis of chromosomal aberrations on a light microscope, by sampling 10 ml peripheral blood from patient before and after administration of the radiopharmaceutical medicinal product (RPMP), preparing cytogenetic preparations for biological dosimetry by analyzing chromosomal aberrations, then calculating induction of radiation markers (Δ F) as difference in frequencies on 'day 3' and 'day 0', performing biological dosimetry with an assessment of the side dose of total internal irradiation (D), and if the increase in Δ F due to the introduction of RFLP is not statistically different from zero, as is the calculated dose D, then determining that the examined patient does not belong to the radiation risk group from the side effects of RFLP. USE - The method is useful for assessing radiation safety of radiopharmaceutical during radiosynovectomy of the knee joint. DETAILED DESCRIPTION - Method for assessing radiation safety of radiopharmaceutical (albumin microspheres labeled with rhenium-188 (188Re)) during radiosynovectomy of the knee joint involves sampling peripheral blood, obtaining a suspension sample containing lymphocytes of the first mitosis, and performing cytogenetic analysis of chromosomal aberrations on a light microscope, by before the administration of the radiopharmaceutical medicinal product (RPMP), sampling 10 ml peripheral blood from patient - 'day 0', then on the 3rd day after the administration of the RFMP 'day 3', preparing cytogenetic preparations for biological dosimetry by analyzing chromosomal aberrations: paired fragments, centric rings and dicentrics with a total number of analyzed metaphases per sample of at least 300, which is a quantitative indicator of radiation exposure in the form of induction of the sum of chromosomal aberrations over the period: 'day 0'-'day 3', for which the frequency of aberrations F is calculated using the formula: 100x (ace+rc+dic)/cells (I), where ace is paired fragments, rc is centric rings, dic is dicentrics, cells is the number of analyzed metaphases, then calculating induction of radiation markers (Δ F) as difference in frequencies on 'day 3' and 'day 0', performing biological dosimetry with an assessment of the side dose of total internal irradiation (D), and if the increase in Δ F due to the introduction of RFLP is not statistically different from zero, as is the calculated dose D, then determining that the examined patient does not belong to the radiation risk group from the side effects of RFLP. |
| IPC 分类号 | A61K-047/42 ; A61M-036/00 ; A61P-019/02 ; G01N-033/49 |
| 国家 | 俄罗斯 |
| 专业领域 | 生物科学 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/15387 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | FEDERAL STATE BUDGETARY INST (FSBI-C) |
| 推荐引用方式 GB/T 7714 | KHVOSTUNOV I K,KRYLOV V V,KOROVCHUK O N,et al. Assessing radiation safety of radiopharmaceutical during radiosynovectomy of knee joint involves sampling peripheral blood, obtaining sample having lymphocytes of first mitosis and performing cytogenetic analysis of chromosomal aberrations. RU2024124502-A; RU2834468-C2[P]. 2024. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论